Cassiopeia study multiple myeloma
WebMultiple myeloma is the result of clonal proliferation of malignant plasma cells. 3 These plasma cells retain much of their normal biology, including bone marrow residence and secretion of large quantities of monoclonal antibody. 4 Myeloma is also highly heterogeneous both clinically and genetically.
Cassiopeia study multiple myeloma
Did you know?
Web12 Nov 2024 · Moreau, P. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly … Web22 Oct 2024 · Topline findings from the second part of the phase 3 CASSIOPEIA clinical trial showed that the primary end point of progression-free survival (PFS) was met with …
Web28 Sep 2024 · As reported in The Lancet Oncology by Philippe Moreau, MD, and colleagues, an interim analysis of part 2 of the phase III CASSIOPEIA trial has shown … Web19 Jul 2024 · Based on data from part 1 of the phase III CASSIOPEIA trial, in September 2024, the FDA granted approval to daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) for adults with newly diagnosed multiple myeloma who are eligible for ASCT. 6,7 An interim analysis from part 2 of the trial …
Web21 Oct 2024 · Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excess proliferation of plasma cells. 1 Multiple myeloma is … Web11 Apr 2024 · Background aims Adoptive cell therapy with chimeric antigen receptor (CAR)-expressing natural killer (NK) cells is an emerging approach that holds promise in multiple myeloma (MM). However, the generation of CAR-NK cells targeting CD38 is met with obstacles due to the expression of CD38 on NK cells.
WebEri O’uchi's 7 research works with 134 citations and 220 reads, including: Pretreatment 18F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model ...
Web3 Jun 2024 · Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) is the most effective tool to define a deep response in multiple myeloma (MM). We conducted … goshen walmart eye centerWebThe primary end point was the rate of MRD negativity at the end of planned treatment up to 8 cycles for the combination therapy using multiparametric flow cytometry for patients … goshen warriors footballWeb5 Jun 2024 · In the phase 3 DETERMINATION trial, patients with newly diagnosed multiple myeloma were randomly assigned to treatment with lenalidomide, bortezomib, and dexamethasone with and without an autologous stem cell transplant (ASCT). All patients received lenalidomide maintenance until progression. goshen warriorsWeb6 Jul 2024 · CASSIOPEIA is the first study showing the clinical benefit of daratumumab plus standard of care in transplant-eligible patients with newly diagnosed multiple myeloma. Funding: The Intergroupe Francophone du Myélome and Dutch-Belgian Cooperative … goshen warriors jpegWeb9 Jun 2024 · CASSIOPEIA is a two-part, phase III study in patients with newly diagnosed multiple myeloma who are eligible for transplantation. The combination of the anti-CD38 … chief bass memeWebMonthly Plenary Series . Abstracts & Presentations chief bass priorities 2022Web19 Jun 2024 · CASSIOPEIA is the first study showing the clinical benefit of daratumumab plus standard of care in transplant-eligible patients with newly diagnosed multiple … goshen walmart phone